Medtronic stock gets FDA label boost from renal denervation data

Medtronic announced on November 3 that its SPYRAL AFFIRM post-approval study showed statistically significant blood-pressure reductions six months after treatment with the Symplicity Spyral renal denervation system. The company presented the findings at the 2026 Transcatheter Cardiovascular Therapeutics meeting and said the study results were published simultaneously in Circulation Cardiovascular Interventions.

The study measured reductions across three settings. Office systolic blood pressure fell by 18.2 mmHg, home blood pressure by 9.4 mmHg and 24-hour ambulatory blood pressure by 9.7 mmHg, each with a p-value below 0.0001. Medtronic said antihypertensive medication use was unchanged at six months, averaging 3.6 medicines per patient.

FDA label expands clinical evidence

The company also said the U.S. Food and Drug Administration approved an update to the Symplicity Spyral Multi-Electrode Renal Denervation Catheter labeling. The revised labeling incorporates additional clinical data for patients with isolated systolic hypertension, chronic kidney disease up to stage 3b and type 2 diabetes. Medtronic said the approved indication itself remains unchanged.

The findings came from a prospective, multicenter, single-arm study designed with the FDA to provide real-world evidence in U.S. patients with uncontrolled hypertension. The study included diverse patient groups, including women, Black and Hispanic patients and people aged 65 or older. The composite safety endpoint occurred in 2.1% of patients, while Medtronic said nearly nine in ten participants experienced a clinical benefit at six months.

Medtronic's Lara Barghout, president of Interventional Cardiology Therapies, said the broader evidence base is intended to give physicians more information when treating patients with hypertension and high cardiovascular risk. The company said evidence from the wider SPYRAL HTN program, including SPYRAL AFFIRM and the Global SYMPLICITY Registry DEFINE, supported the labeling update. The company's press release contains the study details and management commentary.

What the development means for investors

The update strengthens the clinical case for a cardiovascular therapy that targets patients whose blood pressure remains difficult to control. For investors, the commercial question is whether the wider evidence base translates into greater physician adoption and procedure volumes; the announcement itself does not provide revenue or volume guidance.

Medtronic stock traded at 92.27 euros on Lang & Schwarz at 12:02 p.m. CET on Monday, November 9, 2026. Investors can follow the real-time quote of Medtronic stock for the latest indication.

The broader U.S. healthcare market remains the relevant backdrop for medical-device adoption and procedure demand; see the current S&P 500 market reports.

More news and analyses on Medtronic stock will track clinical adoption, cardiovascular portfolio progress and the next company update.